newsfilter
← Latest News
GlobeNewswire·

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RNXT
  • RenovoRx, Inc. reported $1.1 million in revenue for the full year 2025, marking its first full year of commercializing the RenovoCath device.
  • The company has approximately $13 million in cash on hand following a $10 million gross proceeds private placement closed on March 20, 2026.
  • The Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027.
  • As of March 24, 2026, the trial had randomized 104 patients with 72 observed events, exceeding the 100-patient milestone.
  • RenovoCath adoption expanded to 12 active U.S. cancer centers by early 2026, with 21 additional centers evaluating or preparing for activation.
  • RenovoRx estimates an initial total addressable market of approximately $400 million for RenovoCath as a stand-alone device.
  • Operating expenses for 2025 totaled $13.3 million, driven by commercial infrastructure buildout and continued investment in clinical trials.
  • The company reported a net loss of approximately $11.2 million for the year ended December 31, 2025.
  • Mark Voll was appointed as Chief Financial Officer in February 2026 to support commercial growth.
  • A RenovoCath Medical Advisory Board was established in February 2026 to provide strategic clinical guidance.
  • Shares of common stock outstanding as of March 23, 2026, numbered 45,052,706.
  • The company plans to transition 17 cancer centers from the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026.